Patrick Zweidler-McKay

Company: ImmunoGen

Job title: Senior Medical Director

Seminars:

Looking into IMGN632 Development in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) 5:00 pm

IMGN632, a novel anti-CD123 targeting ADC FDA Breakthrough Therapy Designation (BTD) granted in R/R BPDCN Results from the largest-to-date prospective group of uniformly treated patients with R/R BPDCNRead more

day: Day One